The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2016 | Monoclonal gammopathy of unknown significance (MGUS) & importance of regularly monitoring patients
Irene Ghobrial, MD, of Dana-Farber Cancer Institute, Boston, MA, discusses monoclonal gammopathy of unknown significance (MGUS). It is known that 3% of the population over the age of 50 have MGUS and for many patients it is completely asymptomatic. However, there are patients who actually experience problems, these include: neuropathy, fatigue, nephropathy, and monoclonal gammopathy of renal significance (MGRS). There are still questions around how to follow up patients with MGUS and whether these patients should be followed up regularly or not. There is evidence that suggests that following these patients regularly can potentially prevent multiple myeloma (MM) from suddenly occurring and prevent end organ damage. Recorded at the 2016 American Society of Hematology (ASH) Annual Meeting, held in San Diego, CA.
